General Information of the Protein
Protein ID |
PT01126
|
||||
---|---|---|---|---|---|
Protein Name |
Aurora kinase C
|
||||
Secondarily Protein Name |
Aurora 3
Aurora/IPL1-related kinase 3
Aurora/IPL1/Eg2 protein 2
Serine/threonine-protein kinase 13
Serine/threonine-protein kinase aurora-C
|
||||
Gene Name |
AURKC
|
||||
Secondarily Gene Name |
AIE2
AIK3
AIRK3
ARK3
STK13
|
||||
Sequence |
MSSPRAVVQLGKAQPAGEELATANQTAQQPSSPAMRRLTVDDFEIGRPLGKGKFGNVYLARLKESHFIVALKVLFKSQIEKEGLEHQLRREIEIQAHLQHPNILRLYNYFHDARRVYLILEYAPRGELYKELQKSEKLDEQRTATIIEELADALTYCHDKKVIHRDIKPENLLLGFRGEVKIADFGWSVHTPSLRRKTMCGTLDYLPPEMIEGRTYDEKVDLWCIGVLCYELLVGYPPFESASHSETYRRILKVDVRFPLSMPLGARDLISRLLRYQPLERLPLAQILKHPWVQAHSRRVLPPCAQMAS
Show/Hide
|
||||
Organism |
Homo sapiens, Human
|
||||
Protein Classification |
Enzyme
>
Kinase
>
Protein Kinase
>
Other protein kinase group
>
Other protein kinase AUR family
|
||||
Function |
Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Also plays a role in meiosis and more particularly in spermatogenesis. Has redundant cellular functions with AURKB and can rescue an AURKB knockdown. Like AURKB, AURKC phosphorylates histone H3 at 'Ser-10' and 'Ser-28'. AURKC phosphorylates the CPC complex subunits BIRC5/survivin and INCENP leading to increased AURKC activity. Phosphorylates TACC1, another protein involved in cell division, at 'Ser-228'.
Show/Hide
|
||||
Uniprot ID |
Show/Hide
|
||||
Ensembl ID | |||||
HGNC ID | |||||
Subcellular Location |
Nucleus
Chromosome
Chromosome
Centromere
Cytoplasm
Cytoskeleton
Spindle
|
Clinical Information about the Protein
Target 1 ( Aurora kinase C (AURKC) )
Target Type | Clinical trial Target | ||||
---|---|---|---|---|---|
Disease | 4 Target-related Diseases | 4 | |||
1 | Haematological malignancy [ICD-11: 2B33.Y] | ||||
2 | Prostate cancer [ICD-11: 2C82.0] | ||||
3 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | ||||
4 | Advanced solid tumour [ICD-11: 2A00-2F9Z] | ||||
Clinical Trial Drug(s) | 5 Clinical Trial Drugs | 5 | |||
1 | ABT-348 | Phase 2 | |||
2 | PHA-739358 | Phase 2 | |||
3 | AMG 900 | Phase 1 | |||
4 | GSK1070916 | Phase 1 | |||
5 | SNS-314 | Phase 1 | |||
Discontinued Drug(s) | 1 Discontinued Drug | 1 | |||
1 | MK-6592 | Discontinued in Phase 1 |